Previous 10 | Next 10 |
2024-02-15 14:49:08 ET Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Conference Call February 15, 2024, 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief O...
2024-02-15 07:34:29 ET More on Palatin Tech Palatin to raise ~$10M via securities offering Palatin rises as it completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171M Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data fo...
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) ...
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 PR Newswire CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal...
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire Top-Line Results Expected in February CRANBURY, N.J. , Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE...
Palatin Announces Closing of $10 Million Registered Direct Offering PR Newswire CRANBURY, N.J. , Feb. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medic...
2024-01-30 08:20:13 ET More on Palatin Tech Palatin rises as it completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171M Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data for Palatin Tech Read the full article on Seeki...
2024-01-11 13:38:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips After four long years of volatility and economic uncertainty, there finally appears to be light at the end of the tunnel heading into 2024. As rates start coming down and monetary policy loosen...
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 PR Newswire Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative...
Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi ® has experienced 8 Consecutive Quarters of Double-Digit Prescription Growth Acquisition Adds Another...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 PR Newswire CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (N...
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the c...